 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 ibudilast for the treatment of glioblastoma. This new patent has improved therapeutic claims compared to the first patent which covers MN-166 ibudilast for the treatment of glioblastoma, which was granted last year, and has a later expiration date than the first patent. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than February 2039. 